Abivax (ABVX) Net Income (2022 - 2026)
Abivax (ABVX) posted quarterly Net Income of -$56.7 million for Q1 2026, down 3.01% year-over-year from -$58.5 million in Q1 2025, and up 30.72% quarter-over-quarter from -$81.9 million in Q4 2025.
Abivax (ABVX) Net Income (2022 - 2026) Analysis & Trends
Abivax's Net Income history runs 5 years deep, the most recent figure standing at -$56.7 million for Q1 2026.
- In Q1 2026, Net Income fell 3.01% year-over-year to -$56.7 million; the TTM figure through Mar 2026 stood at $221.5 million (up 2427.23% YoY), while the FY2025 annual figure was -$377.7 million, down 100.62% from the prior year.
- Net Income for Q1 2026 stood at -$56.7 million, up from -$81.9 million in the prior quarter.
- The five-year high for Net Income was $414.9 million in Q3 2025, with the low at -$137.1 million in Q4 2023.
- The 5-year median for Net Income is -$55.1 million (2025), against an average of $6.7 million.
- Peak annual rise in Net Income reached 72.91% in 2025, while the deepest fall reached 218.29% in 2025.
- Abivax's Net Income stood at -$66.1 million in 2022, then plunged by 107.34% to -$137.1 million in 2023, then surged by 69.33% to -$42.0 million in 2024, then slumped by 94.84% to -$81.9 million in 2025, then soared by 30.72% to -$56.7 million in 2026.
- Business Quant data shows ABVX's Net Income at -$56.7 million in Q1 2026, -$81.9 million in Q4 2025, and $414.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | -56.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.74 Mn |
| Dec 31, 2025 | -81.90 Mn |
| Sep 30, 2025 | 414.93 Mn |
| Jun 30, 2025 | -54.80 Mn |
| Mar 31, 2025 | -55.09 Mn |
| Dec 31, 2024 | -42.03 Mn |
| Sep 30, 2024 | 239.96 Mn |
| Jun 30, 2024 | -134.08 Mn |
| Mar 31, 2024 | 46.57 Mn |
| Dec 31, 2023 | -137.07 Mn |
| Dec 31, 2022 | -66.11 Mn |